Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) Stock Most Popular Amongst Retail Investors Who Own 57%, While Private Companies Hold 30%
Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) Stock Most Popular Amongst Retail Investors Who Own 57%, While Private Companies Hold 30%
Key Insights
主要见解
- Kangmei Pharmaceutical's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public
- The top 25 shareholders own 43% of the company
- 13% of Kangmei Pharmaceutical is held by Institutions
- 康美药业的重要零售投资者所有权表明,关键决策受到来自更大公众股东的影响。
- 前25名股东拥有公司43%的股份。
- 机构持有康美药业的13%。
A look at the shareholders of Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) can tell us which group is most powerful. With 57% stake, retail investors possess the maximum shares in the company. Put another way, the group faces the maximum upside potential (or downside risk).
观察康美药业股份有限公司(SHSE:600518)的股东,我们可以看出哪个群体最有力。以57%的持股比例,零售投资者拥有公司的最大股份。换句话说,该群体面临着最大的上行潜力(或下行风险)。
And private companies on the other hand have a 30% ownership in the company.
另一方面,私人公司拥有该公司30%的所有权。
Let's delve deeper into each type of owner of Kangmei Pharmaceutical, beginning with the chart below.
让我们深入研究康美药业的每种所有者类型,从下面的图表开始。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240625/0-8b7cf00feb191d8964a20af49e44daaf-0-4cfcc3fd6612c605282ce22173b075bf.png/big)
What Does The Institutional Ownership Tell Us About Kangmei Pharmaceutical?
机构投资者拥有康美药业的相当多的持股。这表明职业投资者对其具有一定的信誉度。但我们不能仅仅依赖这个事实,因为机构有时会像其它人一样做出糟糕的投资。当多个机构拥有一种股票时,总会存在它们处于“拥挤交易”的风险。当这样的交易出错时,多方可能会竞相迅速售出股票。在一个没有增长历史的公司里,这种风险更大。您可以在下面看到康美药业的历史收益和营业收入,但请记住,故事总是更复杂的。
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
机构投资者通常将自己的回报与常见的指数回报进行比较。因此,他们通常会考虑购买包括在相关基准指数中的较大公司。
As you can see, institutional investors have a fair amount of stake in Kangmei Pharmaceutical. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Kangmei Pharmaceutical's historic earnings and revenue below, but keep in mind there's always more to the story.
如您所见,机构投资者在康美药业中拥有相当多的持股。这表明职业投资者对其具有一定的信誉度。但我们不能仅仅依赖这个事实,因为机构有时会像其它人一样做出糟糕的投资。当多个机构拥有一种股票时,总会存在它们处于“拥挤交易”的风险。当这样的交易出错时,多方可能会竞相迅速售出股票。在一个没有增长历史的公司里,这种风险更大。您可以在下面看到康美药业的历史收益和营业收入,但请记住,故事总是更复杂的。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240625/0-8b7cf00feb191d8964a20af49e44daaf-1-fcad21c852717cd96f9262feb068542d.png/big)
Hedge funds don't have many shares in Kangmei Pharmaceutical. Our data shows that Guangdong Shennong Enterprise Management Partnership (Limited Partnership) is the largest shareholder with 25% of shares outstanding. For context, the second largest shareholder holds about 4.7% of the shares outstanding, followed by an ownership of 3.3% by the third-largest shareholder.
对于康美药业,对冲基金并没有持有许多股份。我们的数据显示,广东神农企业管理合伙企业(有限合伙)是最大的股东,持有25%的流通股。为了进一步了解情况,第二大股东持有的流通股约占流通股总数的4.7%,第三大股东持有的流通股的比例为3.3%。
A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.
对我们的所有权数据进行更深入的研究表明,前25名股东的持股总额不到注册表的一半,表明有一个小股东的大群体,其中没有单个股东拥有多数股份。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.
虽然研究公司的机构所有权数据是有意义的,但考虑到分析师的看法,了解风向也是有意义的。我们的信息表明,该股票没有任何分析师的覆盖,因此它可能鲜为人知。
Insider Ownership Of Kangmei Pharmaceutical
康美药业内部持股
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
虽然内部人士的精确定义可能是主观的,几乎每个人都认为董事会成员是内部人士。管理层最终向董事会负责。但是,如果他们是创始人或CEO,经理成为执行董事会成员并不罕见。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
当内部人持股情况表明领导层思考和公司真正所有者一样时,内部所有权是积极的。然而,高达内部人士所有权也可能为公司内的小团体带来巨大的权力。在某些情况下,这可能是负面的。
Our data suggests that insiders own under 1% of Kangmei Pharmaceutical Co., Ltd. in their own names. But they may have an indirect interest through a corporate structure that we haven't picked up on. It is a pretty big company, so it would be possible for board members to own a meaningful interest in the company, without owning much of a proportional interest. In this case, they own around CN¥97k worth of shares (at current prices). Arguably, recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.
我们的数据显示,康美药业股份有限公司的内部人士持有少于1%的股份。但他们可能通过我们还没掌握的公司结构间接持有利益。这是一家相当大的公司,所以董事会成员拥有公司的重要利益,而不拥有相应的比例利益是可能的。在这种情况下,他们持有价值约为97,000元人民币的股份。值得注意的是,最近的买卖和卖出同样重要。您可以点击此处查看内部人士是否一直在买卖。
General Public Ownership
一般大众所有权
The general public, mostly comprising of individual investors, collectively holds 57% of Kangmei Pharmaceutical shares. With this amount of ownership, retail investors can collectively play a role in decisions that affect shareholder returns, such as dividend policies and the appointment of directors. They can also exercise the power to vote on acquisitions or mergers that may not improve profitability.
大多数股东是由个人投资者组成的普通公众,集体持有康美药业的57%股份。有这么多的所有权,个人投资者可以集体对影响股东回报的决策发挥作用,如股息政策和董事的任命。他们还可以行使投票权,对可能不会提高盈利能力的收购或兼并进行投票。
Private Company Ownership
私有公司的所有权
It seems that Private Companies own 30%, of the Kangmei Pharmaceutical stock. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
私人公司拥有康美药业股份的30%。这个事实本身很难得出结论,因此值得研究拥有这些私人公司的公司。有时内部人士或其他相关方通过一个单独的私人公司拥有公共公司的股份。
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand Kangmei Pharmaceutical better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Kangmei Pharmaceutical .
总是值得思考各种股东所拥有的股份。但要更好地了解康美药业,我们需要考虑许多其他因素。因此,您应该知道我们发现的1个警示信号。
Of course this may not be the best stock to buy. Therefore, you may wish to see our free collection of interesting prospects boasting favorable financials.
当然,这也可能不是最好的股票交易。因此,您可能想看看我们免费的潜力股票收藏,这些股票具有有利的财务状况。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。